Suppr超能文献

自体和异体骨髓移植患者血清促红细胞生成素的变化

Serum erythropoietin changes in autologous and allogeneic bone marrow transplant patients.

作者信息

Ireland R M, Atkinson K, Concannon A, Dodds A, Downs K, Biggs J C

机构信息

Department of Haematology, St Vincent's Hospital, Darlinghurst, Sydney, Australia.

出版信息

Br J Haematol. 1990 Sep;76(1):128-34. doi: 10.1111/j.1365-2141.1990.tb07847.x.

Abstract

Sequential changes in serum erythropoietin (sEPO) levels were measured by radioimmunoassay in six patients receiving autologous rescue (AR) and 11 patients receiving an allogeneic bone marrow transplant (BMT) for malignant disease. Longitudinal studies showed an inverse relationship between sEPO and haemoglobin levels in the autologous rescue and allogeneic transplant patients throughout the 130 d post-transplant study period. Early post-conditioning EPO responses were normal for the haemoglobin level in both groups, but after day 14 post-transplant, erythropoietin production in response to anaemia became impaired in one autologous rescue patient and eight of the 11 allogeneic transplant patients. There was no clear association between late impairment of sEPO production and conditioning therapy, infection, graft-versus-host disease, immunosuppressive therapy or serum creatinine. Blood transfusion requirements were similar for both groups in the first month after transplantation, but from days 31 to 90 post-transplant, BMT patients required an average of 5.5 units per patient compared with 1 unit per patient for the autologous group. Marrow transplant procedures do not affect early EPO responses but may diminish late responses. The potential value of exogenous rHuEPO in hastening engraftment and decreasing transfusion requirements, particularly for those patients who appear to have impaired EPO responses, remains to be shown by clinical trials.

摘要

采用放射免疫分析法对6例接受自体挽救治疗(AR)的患者和11例接受异基因骨髓移植(BMT)治疗恶性疾病的患者的血清促红细胞生成素(sEPO)水平的连续变化进行了测定。纵向研究显示,在移植后130天的研究期间,自体挽救治疗患者和异基因移植患者的sEPO与血红蛋白水平呈负相关。两组在预处理后的早期EPO反应对于血红蛋白水平而言均正常,但在移植后第14天之后,1例自体挽救治疗患者和11例异基因移植患者中的8例对贫血的促红细胞生成素产生受损。sEPO产生的晚期受损与预处理治疗、感染、移植物抗宿主病、免疫抑制治疗或血清肌酐之间无明显关联。两组在移植后第一个月的输血需求相似,但在移植后第31天至90天,BMT患者平均每人需要5.5单位,而自体组患者平均每人需要1单位。骨髓移植程序不影响早期EPO反应,但可能会减弱晚期反应。外源性重组人促红细胞生成素在加速植入和减少输血需求方面的潜在价值,尤其是对于那些似乎EPO反应受损的患者,仍有待临床试验证实。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验